Stockscreener 앱 받기
15.82
1.56%
-0.2384
전일 마감가:
$16.06
열려 있는:
$15.67
하루 거래량:
476.63K
Relative Volume:
0.44
시가총액:
$798.88M
수익:
-
순이익/손실:
$-156.39M
주가수익비율:
-4.2877
EPS:
-3.69
순현금흐름:
$-123.06M
1주 성능:
+0.25%
1개월 성능:
-1.98%
6개월 성능:
+11.65%
1년 성능:
+45.45%
1일 변동 폭
$15.27
$15.88
1주일 범위
$15.26
$16.47
52주 변동 폭
$9.235
$19.00
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
15.80 | 811.77M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.15 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.27 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
754.03 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.05 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.31 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 재확인 | Needham | Buy |
| 2026-01-06 | 재확인 | Needham | Buy |
| 2025-01-31 | 개시 | JMP Securities | Mkt Outperform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-12-18 | 개시 | BofA Securities | Buy |
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - BioSpace
KalVista presents sebetralstat data showing early treatment impact By Investing.com - Investing.com India
Market Trends: How does KalVista Pharmaceuticals Inc perform in inflationary periodsWatch List & Low Risk Growth Stock Ideas - baoquankhu1.vn
KalVista Pharmaceuticals, Inc. (KALV): Investor Outlook with a Promising 115% Upside Potential - DirectorsTalk Interviews
Ekterly use urged for kids with HAE 12 and older in new international guideline - Angioedema News
How Kalvista Pharmaceuticals Inc. (KALV) Affects Rotational Strategy Timing - Stock Traders Daily
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Joplin Globe
KalVista Pharma chief development officer sells $67,668 in stock - Investing.com
KalVista Pharma CCO Sweeny Sold $61,878 in Stock - Investing.com UK
Kalvista Pharma CFO Piekos sells $27,506 in shares By Investing.com - Investing.com Australia
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 5,354 Shares of Stock - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,034 Shares - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $61,890.75 in Stock - MarketBeat
KalVista Pharma CMO Audhya sells $83k in shares By Investing.com - Investing.com South Africa
Kalvista Pharma CEO Palleiko sells $156k in shares to cover tax obligations - Investing.com Australia
KalVista Pharma chief development officer sells $67,668 in stock By Investing.com - Investing.com Canada
Kalvista Pharma CFO Piekos sells $27,506 in shares - Investing.com
KalVista Pharma CMO Audhya sells $83k in shares - Investing.com India
[Form 4] KalVista Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
KalVista (NASDAQ: KALV) CFO details RSU vesting and sell-to-cover sale - Stock Titan
KalVista Pharma CCO Sweeny Sold $61,878 in Stock By Investing.com - Investing.com UK
Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet - Finviz
Skandinaviska Enskilda Banken AB publ Buys 160,128 Shares of KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Bausch Health Companies (BHC) and Insulet (PODD) - The Globe and Mail
KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Investors Eye 113.97% Potential Upside - DirectorsTalk Interviews
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells 1,038 Shares of Stock - MarketBeat
KalVista's Ekterly Recommended as First-Line Treatment for HAE i - GuruFocus
International guideline recommends EKTERLY as first-line HAE therapy - Investing.com Nigeria
International guideline recommends EKTERLY as first-line HAE therapy By Investing.com - Investing.com Australia
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline - BioSpace
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for - PharmiWeb.com
KalVista's Ekterly Recommended as First-Line Treatment for HAE in Adolescents - GuruFocus
KalVista Pharmaceuticals (KALV) Leads in Short Interest Among Bi - GuruFocus
Hereditary Angioedema Clinical Trial Pipeline Expands as 20+ - openPR.com
KalVista (KALV) and Intellia (NTLA) Lead Short Interest Surge in Small-Cap Biotech - GuruFocus
KalVista Pharmaceuticals Q3 2026 Earnings Preview - MSN
(KALV) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Will KalVista Pharmaceuticals Inc. face regulatory challengesMarket Sentiment Review & Daily Stock Trend Reports - mfd.ru
Benjamin Palleiko Sells 3,354 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock - MarketBeat
Will KalVista Pharmaceuticals Inc. stock benefit from automationJuly 2025 Retail & Weekly High Return Forecasts - mfd.ru
KalVista Pharmaceuticals (KALV) Stock Analysis: Unpacking A 123% Potential Upside - DirectorsTalk Interviews
Hereditary Angioedema Market to Surpass USD 3 Billion Baseline in 2023, Set for Robust Growth Through 2034 Across 7MM with 7,000 Diagnosed US Cases | DelveInsight - Barchart.com
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of All - pharmiweb.com
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - BioSpace
(sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - Business Wire
Travel Stocks: Should I hold or sell KalVista Pharmaceuticals Inc nowM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion (KALV) - Seeking Alpha
Is KalVista Pharmaceuticals Inc. a turnaround storyMarket Risk Report & Momentum Based Trading Signals - mfd.ru
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Market Catalysts: Does Global Blue Group Holding AG Equity Warrant have a sustainable dividendTrend Reversal & Safe Capital Preservation Plans - baoquankhu1.vn
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.19%
1.03%
자본화:
|
볼륨(24시간):